1. Home
  2. Browse Decisions
  3. F.3d
  4. 903 F.3d
  5. 903 F.3d 1310 (2018)
 

ACORDA THERAPEUTICS v. ROXANE LABORATORIES

2017-2078, 2017-2134.

903 F.3d 1310 (2018)

ACORDA THERAPEUTICS, INC., Plaintiff-Appellant, Alkermes Pharma Ireland Limited, Plaintiff-Appellee, v. ROXANE LABORATORIES, INC., Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Defendants-Cross-Appellants.

United States Court of Appeals, Federal Circuit.

Decided: September 10, 2018.

Attorney(s) appearing for the Case

BRUCE M. WEXLER , Paul Hastings LLP, New York, NY, argued for plaintiff-appellant. Also represented by STEPHEN BLAKE KINNAIRD , IGOR VICTOR TIMOFEYEV , Washington, DC; GARRARD R. BEENEY , WENYING ANGELA CHANG , STEPHEN J. ELLIOTT , Sullivan & Cromwell LLP, New York, NY; ANTHONY MICHAEL , JANE G. WASMAN , Acorda Therapeutics, Inc., Ardsley, NY.

MARYELLEN NOREIKA , Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE, for plaintiff-appellee. Also represented by JEREMY A. TIGAN .

CHARLES B. KLEIN , Winston & Strawn LLP, Washington, DC, argued for defendants-cross-appellants. Defendants-cross-appellants Roxane Laboratories, Inc., Teva Pharmaceuticals USA, Inc. also represented by ANDREW CURTIS NICHOLS ; BRYCE COOPER , GEORGE C. LOMBARDI , REID SMITH , Chicago, IL.

ROBERT FLORENCE , Parker Poe Adams & Bernstein LLP, Atlanta, GA, for defendant-cross-appellant Mylan Pharmaceuticals Inc. Also represented by MICHEAL L. BINNS , KAREN L. CARROLL .

SARAH ANNE KAGAN , Banner and Witcoff, Ltd., Washington, DC, for amicus curiae Biotechnology Innovation Organization. Also represented by MELISSA A. BRAND , LISA MEREDITH HEMMENDINGER ; HANSJORG SAUER , Biotechnology Innovation Organization, Washington, DC.

SCOTT E. KAMHOLZ , Covington & Burling LLP, Washington, DC, for amicus curiae Pharmaceutical Research and Manufacturers of America. Also represented by BRIANNE BHARKHDA ; DAVID EVAN KORN , Pharmaceutical Research and Manufacturers Association of America, Washington, DC.

Opinion dissenting filed by Circuit Judge NEWMAN.

Before us are patents that claim the administration of a medication containing the active ingredient 4-aminopyridine (4-AP) to improve walking in individuals with multiple sclerosis. Acorda Therapeutics, Inc., holds New Drug Application No. 022250, approved by the U.S. Food and Drug Administration...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases